The Stagnation Genome: Manufacturing Disorder
Why Industrial Companies Stagnate Differently — and How the Genome Configures Itself on the Plant Floor
A DNA double helix diagram showing five stagnation genes (PDG, EMG, CBG, SCG, ISG) weaving together at four crossover points, each labeled with one of four manufacturing configurations: Capex Cathedral, Engineering Echo Chamber, Calcified Plant, and BOM Cemetery.
THE STAGNATION GENOME
Manufacturing Disorder — How Five Genes Configure Into Four Failure Modes
PDG
Performance Decline Gene
EMG
Environmental Misalignment Gene
CBG
Cognitive Blindness Gene
SCG
Structural Calcification Gene
ISG
Innovation Suppression Gene
THE CAPEX CATHEDRAL
EMG-dominant · sunk cost as strategy
Optimized for a market that no longer exists
THE ENGINEERING ECHO CHAMBER
CBG + ISG · technical without commercial
Better every year, less relevant every year
THE CALCIFIED PLANT
SCG-dominant · 17-signature paralysis
Decision velocity collapses, no one notices
THE BOM CEMETERY
PDG + ISG · 800 SKUs, 74 profitable
Profitable core suffocates under sprawl
Most plants express 2 or 3 configurations simultaneously.
The configurations interact multiplicatively — each one prevents the others from being addressed.
toddhagopian.com · The Stagnation Genome diagnostic
Summary
The Stagnation Genome — the five-gene framework for diagnosing organizational decline — does not express identically across every industry. In B2B manufacturing, the genome configures into four recognizable presentations: The Calcified Plant (structural calcification dominant), The Engineering Echo Chamber (cognitive blindness fused with innovation suppression), The Capex Cathedral (environmental misalignment trapped behind sunk-cost strategy), and The BOM Cemetery (portfolio sprawl plus performance decline). Each configuration produces a distinct manufacturing-specific failure mode that conventional consulting frameworks systematically misdiagnose. This article maps how the genome actually expresses on the plant floor, why industrial companies stagnate differently than service businesses, and which configuration most likely explains the operating performance you’re currently rationalizing as a market problem. The diagnostic is uncomfortable. The treatment is harder. The cost of refusing to look is the same one Whirlpool refrigeration paid for thirty-six months — half a million dollars a day.
The Manufacturing Difference
I have run the Stagnation Genome diagnostic across enough industries now to know that the genes activate the same way everywhere. What changes is the configuration: the specific way the five genes combine, which gene leads, which gene amplifies, and which symptoms surface first.
Manufacturing has its own physiology, and that physiology produces a distinct disorder. Service businesses can pivot in quarters because their assets are people and software. Manufacturing companies cannot. They are anchored to physical capital, bills of material, supplier networks, plant footprints, regulatory certifications, and engineering cultures that took twenty years to build and would take ten to dismantle. Those anchors are exactly what creates competitive advantage when the environment is stable. They are exactly what creates Stagnation Syndrome when the environment moves.
Most diagnostic frameworks miss this. They treat decline as a strategic problem when, in industrial settings, it is far more often a configurational problem — a specific pattern of how the five genes have woven themselves into the operational reality of the plant. You cannot fix it from a deck. You fix it by recognizing which configuration you are running and applying the corresponding intervention.
There are four configurations I have seen repeatedly. They are not exhaustive. They are the ones that explain roughly 80 percent of the manufacturing turnaround work I have done.
Configuration One: The Calcified Plant
The dominant gene is the Structural Calcification Gene (SCG). Everything else is downstream.
The Calcified Plant looks fine on a tour. Equipment is running. Operators are busy. The dashboards show throughput. What is not visible to a casual visitor is the time tax that has accumulated invisibly over the last fifteen years. Engineering change notices that used to take three days now take six weeks because somewhere along the way, three more departments were added to the approval chain — each addition justified by a specific failure that occurred a decade earlier. The maintenance budget has been cut three years in a row, with each cut framed as “discipline” rather than as the deferred liability it actually is. Setup times that should have been falling through SMED practice are quietly stretching because the operators who knew the changeovers retired and nobody documented what they did.
The Calcified Plant is not poorly run. It is run by people who are trying very hard inside a system that has become structurally incapable of moving at the speed the market now requires. When I sat in a Whirlpool refrigeration plant in 2012 and learned that routine engineering changes required seventeen signatures, I did not encounter villains. I encountered a generation of leaders who had each, individually, made a defensible choice to add one more control. Cumulatively, those choices had produced a decision velocity that competitors with eight signatures were beating by a factor of five.
You diagnose The Calcified Plant by stopwatching the actual flow of decisions, not by looking at the org chart. If you cannot answer the question “how long does it take this plant to change a vendor on a B-grade component?” within ten percent accuracy, you do not yet know whether you have this configuration. Most operators discover, on measurement, that the answer is two to four times longer than they assumed.
Configuration Two: The Engineering Echo Chamber
The Engineering Echo Chamber is the configuration that destroyed a generation of American industrial leadership in segments where Asian competitors arrived with less capability and more market intimacy. The dominant pairing is the Cognitive Blindness Gene fused with the Innovation Suppression Gene.
The signature symptom is that the company has lost the ability to distinguish between a technical improvement and a customer-relevant improvement. Engineering teams pour resources into the next revision of the existing platform — better tolerances, tighter specs, marginal performance gains — while the actual buying criterion in the market has shifted to total cost of ownership, lead time, configurability, or simply “does it show up when you said it would.” The product gets technically better every year and commercially worse every year, and nobody inside the company can explain why because the internal definition of “better” has decoupled from the external definition of “valuable.”
This pattern is so common in industrial settings that MIT Sloan Management Review has documented it explicitly: established firms are actually frequent originators of radical invention, but the organizational design needed to translate invention into market success is what most incumbents lack. (See How to Succeed with Radical Innovation, MIT Sloan Management Review.) The Engineering Echo Chamber is the operational expression of that design failure. The capability is there. The compass is broken.
You will recognize this configuration if your senior product team can recite spec advantages over competitors but cannot tell you which three customers said the spec advantages mattered enough to pay a premium. You will recognize it if “voice of the customer” in your strategic reviews is filtered through the Sales VP rather than gathered directly. You will recognize it if every innovation proposal has to demonstrate how it reinforces the existing platform — which guarantees that no proposal will ever address the platform itself.
Configuration Three: The Capex Cathedral
This is the configuration most commonly mistaken for a strategy problem when it is actually a stagnation problem. The Environmental Misalignment Gene dominates, but it is reinforced by something almost unique to manufacturing: capital sunk-cost worship.
A manufacturing company built a $40 million automated line in 2014 to serve a demand profile that existed in 2014. By 2022, that demand profile had eroded — customers wanted shorter runs, more configurability, faster changeovers — but the line was still there, still depreciating on the books, still requiring its volume to absorb fixed cost. So the strategy bent itself around the asset. Pricing decisions, product decisions, even customer-segmentation decisions all got filtered through the question “but how do we keep the line full?”
This is how you end up optimized for a market that no longer exists. The Capex Cathedral is the configuration where the sunk capital has become the actual strategy, even though no one would write that sentence on a slide. McKinsey’s research on Industry 4.0 transformations found that companies with successful pilots routinely fail to scale them, and a substantial portion of that failure traces to exactly this dynamic: the legacy asset’s economics dictate which transformations are politically survivable. (See Capturing the true value of Industry 4.0, McKinsey.) The transformation that would actually capture the new market would also strand the old line, and so it doesn’t happen — until a competitor with no sunk capital builds the right asset for the new market and the strategic question becomes moot.
The diagnostic for this configuration is brutally simple. Ask: if we were starting from scratch today, with no installed base and no existing equipment, would we build what we currently operate? If the honest answer is no, you are running a Capex Cathedral. The longer you wait to acknowledge it, the more the cathedral costs.
Configuration Four: The BOM Cemetery
The fourth configuration is a marriage between the Performance Decline Gene and the Innovation Suppression Gene, expressed through portfolio sprawl. I call it the BOM Cemetery because the bill of materials has become a graveyard of products that no longer sell, no longer make money, and no longer serve a strategic purpose — but cannot be killed because each one has an internal defender.
The math here is consistent enough across industries that I now expect it before I see it. In a typical industrial portfolio of 800 active SKUs, the recursive 80/20 analysis usually reveals that something close to 70 SKUs generate more than 100 percent of the profit, while several hundred SKUs are quietly destroying value through complexity costs that standard accounting systems do not allocate properly. The complexity tax is invisible because cost accounting is averaged. The standard-cost system tells you every SKU is profitable. Activity-based costing tells you that more than half are not. Most companies never look, because looking would force a decision that is politically painful.
The BOM Cemetery is the most reversible of the four configurations, which is why it is also the most frustrating that companies refuse to address it. A disciplined SKU rationalization combined with strategic price increases on the long tail typically frees 30 to 50 percent of operating capacity inside ninety days. The block is never analytical. It is always political. Every dead SKU is somebody’s pet. Every dead customer is somebody’s relationship. The leader who is willing to absorb the political cost of cleaning the cemetery often finds the entire P&L moves before any of the harder configurations need to be addressed.
How the Configurations Interact
Most manufacturing companies in stagnation are running two configurations simultaneously. The Calcified Plant plus the BOM Cemetery is the most common pairing — bureaucratic decision velocity meets portfolio sprawl, and the company cannot rationalize SKUs because it cannot rationalize anything quickly. The Capex Cathedral plus the Engineering Echo Chamber is the second most common — the company optimized the wrong asset and now its engineers are improving the wrong thing on top of the wrong asset.
What multiplies the damage is that the configurations are not independent. A Calcified Plant cannot launch the new product the Engineering Echo Chamber finally proposes. A BOM Cemetery cannot be cleaned while a Capex Cathedral demands volume to fill the line. Each configuration creates the conditions that prevent the others from being addressed, which is why so many manufacturing turnaround attempts plateau after the first wave of obvious wins. The visible problem gets fixed. The configurational pattern that produced the problem stays intact.
This is also why the consulting-industrial complex has a structural conflict of interest in industrial settings. Consulting engagements are typically scoped to address one configuration — usually the most operationally visible one — at a price point that pays well for eighteen months. The deeper configurational work, the work that would actually reverse the stagnation rather than relieve a symptom of it, is rarely scoped because it threatens the economic logic of the engagement. The honest diagnosis takes a week. The treatment takes two years. The economics of consulting prefer the inverse.
The Manufacturing-Specific 90-Day Question
The general 90-Day Question — what would you do if you had ninety days to transform this business or it dies — works in any setting. In manufacturing, I have found it more useful to run a configuration-specific variant.
For The Calcified Plant: which approval, if eliminated this quarter, would change decision velocity by more than 20 percent? Most plant teams can name it inside thirty seconds. It has usually existed for over a decade for reasons no one can defend.
For The Engineering Echo Chamber: which engineering project currently in flight would the customer not pay an additional dollar for? Again, the team usually knows. The project survives because killing it would embarrass the engineer who proposed it three years ago, who is now a director.
For The Capex Cathedral: if we wrote off the existing line tomorrow, what would we build instead, and how fast could we have it producing? The honesty of the answer tells you whether the cathedral can be deconsecrated voluntarily or whether the market will eventually deconsecrate it for you.
For The BOM Cemetery: which 200 SKUs could we discontinue this quarter without losing a single customer who is currently profitable? The number is almost always larger than the team’s first guess.
None of these questions require a study. They require leadership willing to act on what is already known. That, in the end, is the actual disease — and the actual treatment is the same regardless of configuration. The genome is diagnosable. The configurations are recognizable. The interventions are well understood. What separates the companies that reverse stagnation from the companies that become case studies is whether the leadership team has the discipline to look at the configuration honestly and the courage to act before the configuration becomes terminal.
Most companies will not. The ones that do tend to dominate their categories for the next decade.
Todd Hagopian is the founder of Stagnation Assassins and the author of Stagnation Assassin: The Anti-Consultant Manifesto (Koehler Books, July 2026). He has led industrial transformations at Berkshire Hathaway, Illinois Tool Works, Whirlpool Corporation, and JBT Marel, generating over $3 billion in documented shareholder value across five turnarounds. The Stagnation Genome framework is the diagnostic foundation of the HOT System and is available at toddhagopian.com.